Anixa Biosciences, Inc.ANIXNASDAQ
Loading
Year-over-year research & development expense growth
Latest
-3.50%
↓ 127% vs avg
Percentile
P56
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
12.78%
Historical baseline
| Period | Value |
|---|---|
| Q1 2026 | -3.50% |
| Q4 2025 | 8.25% |
| Q3 2025 | -20.20% |
| Q2 2025 | -14.82% |
| Q1 2025 | 5.15% |
| Q4 2024 | -23.32% |
| Q3 2024 | 0.00% |
| Q2 2024 | 42.70% |
| Q1 2024 | -16.47% |
| Q4 2023 | 48.44% |
| Q3 2023 | 9.02% |
| Q2 2023 | -6.55% |
| Q1 2023 | -36.62% |
| Q4 2022 | 16.61% |
| Q3 2022 | -16.71% |
| Q2 2022 | -5.60% |
| Q1 2022 | -15.43% |
| Q4 2021 | 0.31% |
| Q3 2021 | 111.96% |
| Q2 2021 | 23.50% |
| Q1 2021 | -50.09% |
| Q4 2020 | 92.97% |
| Q3 2020 | -30.07% |
| Q2 2020 | -17.56% |
| Q1 2020 | 74.01% |
| Q4 2019 | -21.09% |
| Q3 2019 | -14.48% |
| Q2 2019 | -43.51% |
| Q1 2019 | -7.63% |
| Q4 2018 | -17.31% |
| Q3 2018 | 345.64% |
| Q2 2018 | -15.13% |
| Q1 2018 | 121.09% |
| Q4 2017 | -3.07% |
| Q3 2017 | -15.81% |
| Q2 2017 | -4.54% |
| Q1 2017 | 9.22% |
| Q4 2016 | 41.57% |
| Q3 2016 | -25.61% |
| Q2 2016 | -14.29% |